171 related articles for article (PubMed ID: 35646162)
21. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib.
Chen YY; Wang CC; Liu YW; Li WF; Chen YH
PeerJ; 2020; 8():e10382. PubMed ID: 33240675
[TBL] [Abstract][Full Text] [Related]
22. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
Cersosimo RJ
Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
[TBL] [Abstract][Full Text] [Related]
23. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma.
Choi WM; Choi J; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Lee SJ; Kim KM
Hepatol Commun; 2020 Jul; 4(7):1073-1086. PubMed ID: 32626838
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma.
Kim Y; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Goh MJ; Kang W; Kim SU
Eur J Gastroenterol Hepatol; 2023 Feb; 35(2):191-197. PubMed ID: 36574310
[TBL] [Abstract][Full Text] [Related]
25. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O; Demirel A; Hacıoğlu MB; Tastekin D; Karabulut S; Gündogdu A; Sever N; Ayhan M; Çelebi A; Majidova N; Yaşar A; Ağyol Y; Erel P; Kocaaslan E; Güren AK; Arıkan R; Isık S; Ercelep O; Goksu SS; Alandag C; Bilgetekin İ; Caner B; Sahin AB; Gulmez A; Akagunduz B; Kose F; Kaplan MA; Dogan E; Sakalar T; Guven DC; Gurbuz M; Ergun Y; Karaagac M; Turker S; Ozkul O; Yıldız B; Sahin S; Demiray AG; Sari M; Erdogan B; Hacıbekiroglu İ; Çakmak Öksüzoğlu ÖB; Kilickap S; Bilici A; Bayoglu İV; Topaloglu S; Cicin İ
J Chemother; 2024 Jan; ():1-9. PubMed ID: 38263804
[TBL] [Abstract][Full Text] [Related]
26. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
28. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.
El-Khoueiry AB; Trojan J; Meyer T; Yau T; Melero I; Kudo M; Hsu C; Kim TY; Choo SP; Kang YK; Yeo W; Chopra A; Soleymani S; Yao J; Neely J; Tschaika M; Welling TH; Sangro B
Ann Oncol; 2024 Apr; 35(4):381-391. PubMed ID: 38151184
[TBL] [Abstract][Full Text] [Related]
31. Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis.
Yang S; Zhou Y; Zeng L
Adv Clin Exp Med; 2023 Aug; 32(8):839-845. PubMed ID: 37140014
[TBL] [Abstract][Full Text] [Related]
32. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study.
Zhang Y; Fan W; Wang Y; Huang G; Li J
Cancer Control; 2019; 26(1):1073274819872216. PubMed ID: 31466465
[TBL] [Abstract][Full Text] [Related]
33. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
[TBL] [Abstract][Full Text] [Related]
34. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
35. Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort.
von Felden J; Karkmann K; Ittrich H; Gil-Ibanez I; Fründt T; Krause J; Lohse AW; Wege H; Schulze K
Visc Med; 2021 Mar; 37(2):87-93. PubMed ID: 33981749
[TBL] [Abstract][Full Text] [Related]
36. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.
Qin J; Huang Y; Zhou H; Yi S
Front Oncol; 2022; 12():807102. PubMed ID: 35463356
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
[TBL] [Abstract][Full Text] [Related]
39. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shimose S; Hiraoka A; Nakano M; Iwamoto H; Tanaka M; Tanaka T; Noguchi K; Aino H; Ogata K; Kajiwara M; Itano S; Yokokura Y; Yamaguchi T; Kawano H; Matsukuma N; Suga H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Kawaguchi T; Koga H; Torimura T
Cancer Med; 2021 Dec; 10(23):8530-8541. PubMed ID: 34693661
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.
Terashima T; Yamashita T; Takata N; Takeda Y; Kido H; Iida N; Kitahara M; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2021 Feb; 51(2):190-200. PubMed ID: 33197087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
